



**BioMarker**  
STRATEGIES

## ***News Release***

---

**Contact:**  
**Tory Field**  
**410-522-1008**

**tfield@biomarkerstrategies.com**

FOR IMMEDIATE RELEASE  
April 2, 2012

### **BioMarker Strategies' SnapPath™ System Named as Finalist in the 2012 Medical Design Excellence Awards**

**Baltimore, MD**---BioMarker Strategies announced today that the company's SnapPath™ biomarker testing platform has been selected as a finalist in the *In vitro diagnostics* category in the 2012 Medical Design Excellence Awards (MDEA) competition. The instrument, which was developed with funding support from the National Cancer Institute, is an automated live-tumor-cell processing device that enables next-generation biomarker tests, known as Functional Signaling Profiles (FSPs), to guide targeted drug therapy selection.

"It is an honor to be recognized by the MDEA judges," remarked Douglas P. Clark, MD, co-founder and Acting CEO for BioMarker Strategies. "The SnapPath™ platform responds to a growing need for new approaches to solid tumor testing that will reveal how a patient's tumor will respond to targeted cancer therapies."

The Medical Design Excellence Awards ([www.MDEAwards.com](http://www.MDEAwards.com)) are the medical device industry's premier design awards competition and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices. Judges also consider features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.

Finalists in each of the competitions' ten categories were officially announced in the April issue of *Medical Device and Diagnostics Industry* ([www.mddionline.com](http://www.mddionline.com)) magazine. The winners will be announced on May 23, 2012, at a cocktail reception being held in conjunction with the MD&M East event, May 22-24, at the Pennsylvania Convention Center in Philadelphia.

BioMarker Strategies teamed with HS Design (Gladstone, NJ), and Sparton Medical Systems (Strongsville, OH), for the design, engineering and manufacturing of the platform.

#### **About BioMarker Strategies**

BioMarker Strategies is developing the SnapPath™ live tumor cell testing system to enable next-generation biomarker tests for solid-tumor based cancers, including advanced melanoma. The SnapPath™ system incorporates an automated, live-tumor-cell processing device with first-in-class, functional, ex vivo biomarker tests to inform clinical decision making for targeted cancer therapeutics. SnapPath™ stimulates a patient's live tumor cells outside their body to obtain a

NEWS RELEASE

Functional Signaling Profile (FSP™) of the signal transduction network that is not possible using static, genomic biomarkers from dead, fixed tissue. The company is located at the Johns Hopkins Science + Technology Park in East Baltimore. The development of the SnapPath™ system is supported with significant funding from the National Cancer Institute. For more information about BioMarker Strategies, please refer to [www.biomarkerstrategies.com](http://www.biomarkerstrategies.com).

### **About HS Design**

HS Design Inc., located in Gladstone, NJ, is a full-service product development firm focusing on user-driven design for the medical and Life Science industry. The firm is a recognized leader in the field, producing over 400 successful products since its inception some 40 years ago. HSD partners with a wide range of companies, from Fortune 100 firms to start-up ventures, to develop a variety of market-leading surgical tools, diagnostic instruments and consumer healthcare products. Services include contextual research, market strategy, industrial design, packaging, mechanical engineering, FEA simulation, rapid prototyping, V&V and manufacturing liaison. For more information regarding HSD, please visit <http://www.hs-design.com>.

### **About Sparton Medical**

Sparton Medical's operations are comprised of contract development, design, production and fulfillment of complex and sophisticated medical class I, class II, and class III devices. This division of Sparton Corporation (NYSE: SPA) assures product reliability and safety in accordance with Food and Drug Administration ("FDA") guidelines and GMP manufacturing procedures for each product the Company designs and manufactures. Sparton Medical specializes in systems and procedures that meet the requirements of medical OEM and emerging technology customers in the In Vitro Diagnostic, Therapeutic, and Surgical Devices markets.

# # #

*Some of the information in this release contains our projections or other forward-looking statements regarding future events. We wish to caution you that these statements are only predictions and actual events or results may differ materially. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Forward-looking statements included herein are made as of the date hereof, and we undertake no obligation to update publicly such statements to reflect subsequent events or circumstances. Actual results could differ materially from anticipated results.*

# # #